RBGLY - Reckitt Benckiser Group plc

Other OTC - Other OTC Delayed Price. Currency in USD
15.18
-0.23 (-1.52%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close15.41
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,205,262
Market Cap53.67B
Beta1.05
PE Ratio (TTM)6.27
EPS (TTM)2.42
Earnings DateN/A
Forward Dividend & Yield0.55 (3.18%)
Ex-Dividend Date2018-04-12
1y Target Est13.85
Trade prices are not sourced from all markets
  • Reuters5 days ago

    FTSE 100 posts fourth straight week of gains while Reckitt, Shire fall

    Weaker sterling helped Britain's FTSE 100 (.FTSE) outperform European markets on Friday, while consumer giant Reckitt Benckiser tumbled after disappointing results and Shire declined as Allergan pulled out of the running to acquire the company. Sterling fell after Bank of England Governor Mark Carney dampened widespread expectations for an interest rate hike in May. The decline supported export-oriented large-cap stocks, which dominate the FTSE 100.

  • Reuters5 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO, April 20 (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.

  • Reckitt takes hit from stumbling Scholl and price pressure
    Reuters5 days ago

    Reckitt takes hit from stumbling Scholl and price pressure

    Reckitt Benckiser lagged other consumer good makers in the first quarter as further falls in Scholl footcare and lower prices hit the British company's sales growth. Bernstein analysts said Reckitt's like-for-like sales growth was "bottom of class" of the five European food and packaged goods companies that have reported quarterly sales so far, and it shares fell more than 6 percent to their lowest level since the start of 2015. Nestle, Procter & Gamble and Unilever also saw very little pricing growth, as packaged goods makers face pressure from retailers fighting off drug store chains and Amazon.com.

  • The Wall Street Journal5 days ago

    [$$] Failed Foot-Care Gadget Trips Up Reckitt

    Shares in Reckitt fell as much as 9% Friday after the company’s first-quarter sales growth missed expectations. Reckitt blamed Scholl—called Amopé in the U.S.—a foot-care brand it inherited in 2010 as part of its $3.9 billion acquisition of Durex condom makerSSL International in 2010. Scholl has turned into a recurring problem for the U.K. company.

  • Reckitt's Hidden Good News Gives it a Shot at Cleaning Up
    Bloomberg5 days ago

    Reckitt's Hidden Good News Gives it a Shot at Cleaning Up

    Its fall from superstardom doesn't need to be permanent.

  • Financial Times5 days ago

    [$$] Reckitt Benckiser shares slide on stagnant sales growth

    Reckitt Benckiser needed a strong start to 2018 after its worst ever year but first-quarter sales missed expectations, sending the shares down as much as 7 per cent. The company behind Durex condoms, Air ...

  • Financial Times5 days ago

    [$$] Reckitt Benckiser slides 6% after quarterly results miss forecasts

    Reckitt was the biggest faller on Friday on the benchmark FTSE 100 index and the stock was on track for its worst day since February, according to FactSet data. Reckitt said like for like sales rose 2 per cent in the first quarter of 2018, worse than the 2.6 per cent rise that analysts had forecast. The company’s Scholl division, which makes footcare and footwear products like pedicure roller devices was a particular weak spot.

  • The Wall Street Journal5 days ago

    [$$] Reckitt Shares Slide After Sales Miss Expectations

    Reckitt Benckiser disappointed investors with first-quarter sales that missed analysts’ estimates, the latest in a string of disappointments from the owner of Durex condoms and Scholl footcare.

  • Financial Times5 days ago

    [$$] Reckitt Benckiser misses estimate on key sales gauge

    Reckitt Benckiser has kicked off 2018 with like-for-like sales growth of 2 per cent in its first quarter, similar to the previous quarter and up on zero growth in sales in 2017, but still worse than estimates. The Durex condom, Air Wick freshener and Nurofen painkiller group reported revenues of £3.1bn in the first three months of the year, up 49 per cent on the same quarter last year due to the inclusion of the $18bn Mead Johnson infant nutrition business. The like for like sales growth figure missed analyst estimates of 2.6 per cent and sent Reckitt shares dropping 5 per cent in early trade in London.

  • Reuters5 days ago

    Reckitt misses Q1 estimates on Scholl missteps, weak pricing

    British consumer goods maker Reckitt Benckiser reported lower-than-expected quarterly sales growth on Friday, hurt by further weakness in its Scholl footcare business and negative pricing. Consumer packaged goods makers, under pressure to boost revenue, are having trouble raising prices, due in part to intense competition among big retailers fighting off encroachment from the likes of drug store chains and Amazon.com . Volume was up 3 percent, implying that overall pricing was negative.

  • Weak Pricing Hits Reckitt Benckiser's Push to Restore Growth
    Bloomberg5 days ago

    Weak Pricing Hits Reckitt Benckiser's Push to Restore Growth

    Weak pricing of household cleaning items hurt Reckitt Benckiser Group Plc’s sales in the first quarter, slowing the company’s effort to return to growth after its worst-ever year.

  • Reckitt Benckiser Tumbles as Weak Pricing Holds Back Growth
    Bloomberg5 days ago

    Reckitt Benckiser Tumbles as Weak Pricing Holds Back Growth

    Reckitt Benckiser Group Plc fell the most in nearly a decade as weak pricing of household cleaning items hurt sales in the first quarter, slowing the company’s effort to return to growth after its worst-ever ...

  • P&G's vitamin boost could signal more to come
    Reuters5 days ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.

  • Financial Times5 days ago

    [$$] Stocks to watch: Shire, Dunelm, Hammerson, Ericsson, Esure, GE

    Shire traded lower even after Takeda made a fourth offer to buy the drugmaker with a sweetened proposal of £47 per share. The improved offer came after Shire on Thursday said it had rejected Takeda’s proposal ...

  • Interested In Reckitt Benckiser Group plc (LON:RB.)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.8 days ago

    Interested In Reckitt Benckiser Group plc (LON:RB.)? Here’s What Its Recent Performance Looks Like

    Understanding Reckitt Benckiser Group plc’s (LSE:RB.) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense checkRead More...

  • Financial Times8 days ago

    [$$] Stocks to watch: Ashmore, AA, Travis Perkins, JD Sports, Intrum

    Emerging markets fund manager Ashmore was in demand after its third-quarter results showed its strongest net inflows since June 2013, which helped boost assets under management by 10 per cent to $76.5bn. ...

  • Financial Times8 days ago

    [$$] Reckitt Benckiser under pressure after Credit Suisse warning

    Reckitt Benckiser was under pressure after Credit Suisse said the Durex and Clearasil maker was in a vicious spiral of volume losses and price rises. Relatively low research and development spending may ...

  • 5 Standout Numbers From McCormick's Q1 Earnings Report
    Motley Fool23 days ago

    5 Standout Numbers From McCormick's Q1 Earnings Report

    See the metrics that helped power strong profit growth for the spice and flavorings specialist.

  • Reckitt Benckiser CEO gets second pay cut in two years
    Reuters28 days ago

    Reckitt Benckiser CEO gets second pay cut in two years

    Reckitt Benckiser's (RB.L) chief executive Rakesh Kapoor got an 18 percent pay cut in 2017, his second in two years, due to a halving of his long-term incentive benefits, after a year of underperformance at the British consumer goods company. The maker of Durex condoms and Lysol cleaners said on Wednesday Kapoor received total compensation of 12.5 million pounds ($17.7 million) in 2017, down from 15.3 million in 2016. Without the reduction in his long-term incentive plan (LTIP), Kapoor's 2017 compensation would have been 23.7 million pounds.

  • Reuters28 days ago

    Reckitt Benckiser CEO gets second pay cut in two years

    Reckitt Benckiser's (RB.L) chief executive Rakesh Kapoor got an 18 percent pay cut in 2017, his second in two years, due to a halving of his long-term incentive benefits, after a year of underperformance at the British consumer goods company. The maker of Durex condoms and Lysol cleaners said on Wednesday Kapoor received total compensation of 12.5 million pounds ($17.7 million) in 2017, down from 15.3 million in 2016. Without the reduction in his long-term incentive plan (LTIP), Kapoor's 2017 compensation would have been 23.7 million pounds.

  • Pfizer is having a tough time selling its consumer health care business
    American City Business Journalslast month

    Pfizer is having a tough time selling its consumer health care business

    GlaxoSmithKline, Reckitt Benckiser and Johnson & Johnson have each decided not to pursue a deal.

  • Glaxo's Boss Looks Ready to Loosen the Straitjacket
    Bloomberglast month

    Glaxo's Boss Looks Ready to Loosen the Straitjacket

    Emma Walmsley's discipline is earning her the right to do some M&A -- possibly even another run at Pfizer's consumer assets.

  • Reuterslast month

    Back to the drawing board for Reckitt after dropping Pfizer bid

    Reckitt Benckiser's (RB.L) decision to drop its pursuit of Pfizer's (PFE.N) consumer health assets leaves it with a tough job to restore growth to its flat-lining business. With a deal off the table, investors will turn their attention to Reckitt's internal challenges, including the integration of Mead Johnson, the ailing baby formula maker it bought for $17 billion last year, and reigniting sales growth. "The market has been used to Reckitt being the company that consistently delivered ahead-of-market volume growth and last year they didn't," said Reckitt shareholder Steve Clayton at Hargreaves Lansdown.